Search for content, post, videos

Devyser enters agreement with Thermo Fisher Scientific

The companies have signed a collaboration and distribution agreement that gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe.

“Partnering with Thermo Fisher, the leading innovator in the HLA industry, is a great opportunity for Devyser and a significant milestone for our company. Through this strategic partnership, clinical labs, clinicians and patients in the US, Canada and Europe will have broad and fast access to Devyser´s innovative NGS based products for post-transplant monitoring. The agreement is also a quality stamp of our company and our products,” says Fredrik Alpsten, CEO of Devyser.

The agreement

The collaboration and distribution agreement signed gives Thermo Fisher exclusive rights to market and sell, under combined brands, Devyser’s post-transplant portfolio in North America and Europe. Devyser retains the rights to commercialize its post-transplant products in US via its own service laboratory, as a service to US laboratories. Devyser will continue to manufacture all products under the agreement.


“Thermo Fisher is very well-established and positioned in both the US and European market, and with their commercial infrastructure and resources, they can cover both US and Europe efficiently. Our sensitive assays and streamlined work process give labs the ability to provide fast and trusted results. Further, the Devyser post-transplant products are pending IVDR certification for the European market. Together, our brands provide a strong proposition to customers and laboratories across the transplantation field. Devyser will continue to grow and focus on product development in the transplant field,” says Theis Kipling, CCO of Devyser.

Photo: iStock